A. Konsoulova-Kirova (Varna, Bulgaria), A. Charpidou (Athens, Greece)
To stop or not to stop immunotherapy after 2 years in Non Small Cell Lung Cancer (NSCLC)? Results of a cross sectional survey among French thoracic oncologist.
S. Storme (Lyon, France), D. Debieuvre (Mulhouse, France), P. Souquet (Lyon, France), S. Couraud (Lyon, France)
|   |
The therapeutic potential of ADAMTS8 in lung cancer patients without Immune checkpoint inhibitors/EGFR mutation
Y. Tsai (Kaohsiung, Taiwan), Y. Huang (Kaohsiung, Taiwan), C. Chang (Kaohsiung, Taiwan), L. Liu (Kaohsiung, Taiwan), K. Wu (Kaohsiung, Taiwan)
| |
Clinical determinants of immunotherapy outcomes in non-small cell lung cancer patients with checkpoint inhibitor pneumonitis
I. Vathiotis (Athens, Greece), K. Tavernaraki (Athens, Greece), I. Trontzas (Athens, Greece), E. Antonogiannaki (Athens, Greece), E. Koukaki (Athens, Greece), N. Syrigos (Athens, Greece), I. Gkiozos (Athens, Greece), E. Kotteas (Athens, Greece), A. Charpidou (Athens, Greece)
| |
Cellular and plasmatic immune profile of anti-PD-1 therapy in phase IIIB/IV non-small cell lung cancer: relevance of immunosuppressive factors
P. Rodrigues-Santos (Coimbra, Portugal), J. Almeida (Coimbra, Portugal), L. Sousa (Coimbra, Portugal), M. Santos-Rosa (Coimbra, Portugal), F. Barata (Coimbra, Portugal), A. Figueiredo (Coimbra, Portugal)
| |
Long-term outcomes in patients with Non Small Cell Lung Cancer (NSCLC) treated by Immune Checkpoint Inhibitors (ICIs) for a minimal duration of 2 years: a cohort study in a tertiary hospital.
S. Storme (Lyon, France), L. Kiakouama (Lyon, France), M. Darrason (Lyon, France), G. Devouassoux (Lyon, France), M. Duruisseaux (Lyon, France), S. Couraud (Lyon, France)
| |
Pulmonary complications after surgical resection of lung cancer - analysis of thousands cases.
A. Trojnar (Warsaw, Poland), J. Domagala-Kulawik (Warsaw, Poland), A. Sienkiewicz-Ulita (Warsaw, Poland), M. Zbytniewski (Warsaw, Poland), G. Gryszko (Warsaw, Poland), M. Cackowski (Warsaw, Poland), M. Dziedzic (Warsaw, Poland), K. Woznica (Warsaw, Poland), T. Orlowski (Warsaw, Poland), D. Dziedzic (Warsaw, Poland)
| |
Right intrapericardial pneumonectomy; is it still a forbidden procedure?
I. Karampinis (Athens, Greece), G. Hardavella (Athens, Greece), A. Katsipoulakis (Athens, Greece), N. Anastasiou (Athens, Greece)
| |
Povidone Iodine use as effective pleurodesis treatment for prolonged air leak ?
Z. Chaari (Sfax, Tunisia), A. Hentati (Sfax, Tunisia), A. Ben Ayed (Sfax, Tunisia), G. Ben Hlima (Sfax, Tunisia), W. Abid (Sfax, Tunisia), I. Frikha (Sfax, Tunisia)
| |
Longitudinal changes in pulmonary function and patient reported outcomes after lung cancer surgery
H. Park (Seoul, Republic of Korea), S. Shin (Seoul, Republic of Korea), S. Kong (Seoul, Republic of Korea), D. Kang (Seoul, Republic of Korea), G. Lee (Seoul, Republic of Korea), J. Cho (Seoul, Republic of Korea), Y. Shim (Seoul, Republic of Korea), J. Cho (Seoul, Republic of Korea), H. Kim (Seoul, Republic of Korea)
| |
Effect of HIIT-based interventions on exercise capacity in lung cancer survivors: Meta-Analysis
A. Heredia Ciuró (Granada, Spain), J. Martin Nuñez (Granada, Spain), A. Lazo Prados (Granada, Spain), A. Ortiz Rubio (Granada, Spain), A. Calvache Mateo (Granada, Spain), M. Valenza (Granada, Spain)
| |
Characteristics and clinical courses in a monocentric NSCLC cohort with MET exon 14 skipping mutations
G. Rafflenbeul (Berlin, Germany), C. Lips (Berlin, Germany), T. Blum (Berlin, Germany), M. Hollmann (Berlin, Germany), J. Kollmeier (Berlin, Germany), D. Misch (Berlin, Germany), S. Stephan-Falkenau (Berlin, Germany), A. Streubel (Berlin, Germany), S. Thiel (Berlin, Germany), T. Mairinger (Berlin, Germany), T. Bauer (Berlin, Germany), C. Lips (Kleinmachnow, Germany)
| |
Impact of dose modification of immune-checkpoint inhibitors in lung cancer patients during the COVID-19 pandemic.
M. Veron (La Tronche, France), T. Pierret (Lyon, France), M. Perol (Lyon, France), J. Benet (La Tronche, France), N. Denis (La Tronche, France), D. Moro-Sibilot (La Tronche, France), A. Swalduz (Lyon, France), A. Toffart (La Tronche, France)
| |
Osimertinib as neoadjuvant therapy for resectable non-small cell lung cancer: a single-center real-world study
S. Ren (Changsha, China), L. Yang (Changsha, China), Z. Tong (Changsha, China), R. Wang (Changsha, China), W. Han (Changsha, China), F. Yu (Changsha, China), W. Liu (Changsha, China), Y. Hu (Changsha, China)
| |
The impact of the COVID-19 pandemic on delay in diagnosis and management of lung cancer in developing countries
N. Khézami (Tunisia, Tunisia), C. Habouruia (Tunisia, Tunisia), N. Belloumi (Tunisia, Tunisia), B. Khawla (Tunisia, Tunisia), A. Zargouni (Tunisia, Tunisia), I. Bachouch (Tunisia, Tunisia), F. Chermiti (Tunisia, Tunisia), S. Fenniche (Tunisia, Tunisia)
| |
Response evaluation with FDG PET-CT after 2 years of immune checkpoint inhibition
R. Wener (Edegem, Belgium), A. Snoeckx (Edegem, Belgium), L. Carp (Edegem, Belgium), J. Raskin (Edegem, Belgium), C. De Bondt (Edegem, Belgium), J. Van Meerbeeck (Edegem, Belgium), A. Janssens (Edegem, Belgium)
| |
Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation.
R. Gijtenbeek (Leeuwarden, Netherlands), K. De Jong (Leeuwarden, Netherlands), B. Venmans (Leeuwarden, Netherlands), F. Van Vollenhoven (Leeuwarden, Netherlands), A. Van Der Wekken (Groningen, Netherlands), W. Van Geffen (Leeuwarden, Netherlands)
| |